

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSSPTA1617SXX

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS	1		Web Page for STN Seminar Schedule - N. America
NEWS	2	AUG 06	CAS REGISTRY enhanced with new experimental property tags
NEWS	3	AUG 06	FSTA enhanced with new thesaurus edition
NEWS	4	AUG 13	CA/Caplus enhanced with additional kind codes for granted patents
NEWS	5	AUG 20	CA/Caplus enhanced with CAS indexing in pre-1907 records
NEWS	6	AUG 27	Full-text patent databases enhanced with predefined patent family display formats from INPADOCDB
NEWS	7	AUG 27	USPATOLD now available on STN
NEWS	8	AUG 28	CAS REGISTRY enhanced with additional experimental spectral property data
NEWS	9	SEP 07	STN AnaVist, Version 2.0, now available with Derwent World Patents Index
NEWS	10	SEP 13	FORIS renamed to SOFIS
NEWS	11	SEP 13	INPADOCDB enhanced with monthly SDI frequency
NEWS	12	SEP 17	CA/Caplus enhanced with printed CA page images from 1967-1998
NEWS	13	SEP 17	Caplus coverage extended to include traditional medicine patents
NEWS	14	SEP 24	EMBASE, EMBAL, and LEMBASE reloaded with enhancements
NEWS	15	OCT 02	CA/Caplus enhanced with pre-1907 records from Chemisches Zentralblatt
NEWS	16	OCT 19	BEILSTEIN updated with new compounds
NEWS	17	NOV 15	Derwent Indian patent publication number format enhanced
NEWS	18	NOV 19	WPIX enhanced with XML display format
NEWS	19	NOV 30	ICSD reloaded with enhancements
NEWS	20	DEC 04	LINPADOCDB now available on STN
NEWS	21	DEC 14	BEILSTEIN pricing structure to change
NEWS	22	DEC 17	USPATOLD added to additional database clusters
NEWS	23	DEC 17	IMSDRUGCONF removed from database clusters and STN
NEWS	24	DEC 17	DGENE now includes more than 10 million sequences
NEWS	25	DEC 17	TOXCENTER enhanced with 2008 MeSH vocabulary in MEDLINE segment
NEWS	26	DEC 17	MEDLINE and LMEDLINE updated with 2008 MeSH vocabulary
NEWS	27	DEC 17	CA/Caplus enhanced with new custom IPC display formats
NEWS	28	DEC 17	STN Viewer enhanced with full-text patent content from USPATOLD
NEWS	29	JAN 02	STN pricing information for 2008 now available
NEWS	30	JAN 16	CAS patent coverage enhanced to include exemplified prophetic substances
NEWS	31	JAN 28	USPATFULL, USPAT2, and USPATOLD enhanced with new custom IPC display formats
NEWS	32	JAN 28	MARPAT searching enhanced
NEWS	33	JAN 28	USGENE now provides USPTO sequence data within 3 days of publication
NEWS	34	JAN 28	TOXCENTER enhanced with reloaded MEDLINE segment
NEWS	35	JAN 28	MEDLINE and LMEDLINE reloaded with enhancements
NEWS EXPRESS	19	SEPTEMBER 2007:	CURRENT WINDOWS VERSION IS V8.2,

CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),
AND CURRENT DISCOVER FILE IS DATED 19 SEPTEMBER 2007.

NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS LOGIN Welcome Banner and News Items
NEWS IPC8 For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that
specific topic.

All use of STN is subject to the provisions of the STN Customer
agreement. Please note that this agreement limits use to scientific
research. Use for software development or design or implementation
of commercial gateways or other similar uses is prohibited and may
result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 10:43:29 ON 03 FEB 2008

=> file caplus

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'CAPLUS' ENTERED AT 10:43:38 ON 03 FEB 2008

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is
held by the publishers listed in the PUBLISHER (PB) field (available
for records published or updated in Chemical Abstracts after December
26, 1996), unless otherwise indicated in the original publications.
The CA Lexicon is the copyrighted intellectual property of the
American Chemical Society and is provided to assist you in searching
databases on STN. Any dissemination, distribution, copying, or storing
of this information, without the prior written consent of CAS, is
strictly prohibited.

FILE COVERS 1907 - 3 Feb 2008 VOL 148 ISS 6

FILE LAST UPDATED: 1 Feb 2008 (20080201/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

<http://www.cas.org/infopolicy.html>

=> file caplus biosis embase medline

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.48	0.69

FILE 'CAPLUS' ENTERED AT 10:43:58 ON 03 FEB 2008

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'BIOSIS' ENTERED AT 10:43:58 ON 03 FEB 2008

Copyright (c) 2008 The Thomson Corporation

FILE 'EMBASE' ENTERED AT 10:43:58 ON 03 FEB 2008

Copyright (c) 2008 Elsevier B.V. All rights reserved.

FILE 'MEDLINE' ENTERED AT 10:43:58 ON 03 FEB 2008

=> s dihydroisohumulone
L1 33 DIHYDROISOHUMULONE

=> s dihydroisocohumulone
L2 9 DIHYDROISOCOHUMULONE

=> s dihydroisoadhumulone
L3 6 DIHYDROISOADHUMULONE

=> dup rem L1
PROCESSING COMPLETED FOR L1
L4 24 DUP REM L1 (9 DUPLICATES REMOVED)

=> dup rem L2
PROCESSING COMPLETED FOR L2
L5 9 DUP REM L2 (0 DUPLICATES REMOVED)

=> dup rem L3
PROCESSING COMPLETED FOR L3
L6 3 DUP REM L3 (3 DUPLICATES REMOVED)

=> s inflammation
L7 713056 INFLAMMATION

=> s L4 and L7
L8 13 L4 AND L7

=> s L2 and L7
L9 9 L2 AND L7

=> s L3 and L7
L10 2 L3 AND L7

=> s L8 or L9 or L10
L11 13 L8 OR L9 OR L10

=> d L11 1-13 ibib abs

L11 ANSWER 1 OF 13 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2007:1469382 CAPLUS
DOCUMENT NUMBER: 148:93199
TITLE: Reduced isoalpha acid based protein kinase modulation
cancer treatment
INVENTOR(S): Tripp, Matthew L.; Babish, John G.; Bland, Jeffrey;
Hall, Amy Jennae; Konda, Veera; Pacioretty, Linda;
Desai, Anu
PATENT ASSIGNEE(S): Metaproteomics, LLC, USA
SOURCE: PCT Int. Appl., 161pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 8
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007149480	A2	20071227	WO 2007-US14372	20070620
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN,			

TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF,
BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW,
GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ,
BY, KG, KZ, MD, RU, TJ, TM

US 2008026088 A1 20080131 US 2007-820653 20070620
PRIORITY APPLN. INFO.: US 2006-815064P P 20060620
AB Compds. and methods for protein kinase modulation for cancer treatment are
disclosed. The compds. and methods disclosed are based on reduced
isoalpha acids, commonly found in hops.

L11 ANSWER 2 OF 13 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2007:1212798 CAPLUS

DOCUMENT NUMBER: 147:474747

TITLE: Synergistic anti-inflammatory pharmaceutical
compositions comprising iso- α and reduced
iso- α acids isolated from hops, and methods of
use

INVENTOR(S): Babish, John G.; Tripp, Matthew L.; Bland, Jeffrey S.
PATENT ASSIGNEE(S): USA

SOURCE: U.S. Pat. Appl. Publ., 21pp., Cont.-in-part of U.S.
Ser. No. 789,814.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2007249728	A1	20071025	US 2007-590301	20070501
US 2005192356	A1	20050901	US 2004-789814	20040227
WO 2005084680	A1	20050915	WO 2005-US6216	20050226
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			

PRIORITY APPLN. INFO.: US 2004-789814 A2 20040227
WO 2005-US6216 W 20050226

OTHER SOURCE(S): MARPAT 147:474747

AB The invention provides a composition comprising a reduced iso-alpha acid (RIAA) and iso-alpha acid (IAA) isolated from hops, wherein the RIAA and IAA are in a ratio of about 3:1 to about 1:10. The invention also provides a method of reducing inflammation by administering a composition comprising a reduced iso-alpha acid (RIAA) and iso-alpha acid (IAA) isolated from hops, wherein the RIAA and IAA are in a ratio of about 3:1 to about 1:10. Thus, synergy between RIAA and IAA was observed in four combinations--3:1, 3:2, 1:1 and 1:10. Particularly relevant synergy occurred at the 1:1 and 1:10 RIAA:IAA ratios. For these formulations, synergy was seen, resp., at RIAA concns. <0.58 μ g/mL and RIAA concns. >0.31 μ g/ mL.

L11 ANSWER 3 OF 13 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2007:873413 CAPLUS

DOCUMENT NUMBER: 147:243339

TITLE: Synergistic anti-inflammatory pharmaceutical
composition comprising curcuminoid or methylxanthine

INVENTOR(S): Babish, John G.; Tripp, Matthew L.; Bland, Jeffrey S.
 PATENT ASSIGNEE(S): USA
 SOURCE: U.S. Pat. Appl. Publ., 37pp., Cont.-in-part of U.S.
 Ser. No. 789,817.
 CODEN: USXXCO
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2007185213	A1	20070809	US 2007-590424	20070402
US 2005191375	A1	20050901	US 2004-789817	20040227
WO 2005084230	A2	20050915	WO 2005-US6147	20050226
WO 2005084230	A3	20051215		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
 RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 2004-789817 A2 20040227
 WO 2005-US6147 W 20050226

OTHER SOURCE(S): MARPAT 147:243339

AB The invention provides compns. containing a fraction isolated or derived from hops and a methylxanthine. The invention addnl. provides compns. containing a fraction derived from hops and a curcuminoid. The invention also provides methods of using such compns. to reduce inflammation.

L11 ANSWER 4 OF 13 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2007:793487 CAPLUS

DOCUMENT NUMBER: 147:158481

TITLE: Treatment modalities for autoimmune diseases using isoalpha acids, vitamins and minerals

INVENTOR(S): Tripp, Matthew L.; Bland, Jeffrey S.; Lerman, Robert; Hall, Amy J.; Konda, Veera; Desai, Anu

PATENT ASSIGNEE(S): Metaproteomics, LLC, USA

SOURCE: U.S. Pat. Appl. Publ., 26pp., Cont.-in-part of U.S. Ser. No. 326,874.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 11

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2007166418	A1	20070719	US 2007-649584	20070104
US 2003008021	A1	20030109	US 2001-885721	20010620
US 7205151	B2	20070417		
US 2004086580	A1	20040506	US 2003-464410	20030618
US 2004115290	A1	20040617	US 2003-464834	20030618
US 2004151792	A1	20040805	US 2003-689856	20031020
US 7270835	B2	20070918		
US 2007020352	A1	20070125	US 2006-326874	20060106

PRIORITY APPLN. INFO.: US 2001-885721 A2 20010620
 US 2002-420383P P 20021021
 US 2003-450237P P 20030225
 US 2003-400293 B2 20030326

US 2003-401283	B2 20030326
US 2003-464410	A2 20030618
US 2003-464834	A2 20030618
US 2003-689856	A2 20031020
US 2004-866315	B2 20040610
US 2006-326874	A2 20060106

OTHER SOURCE(S): MARPAT 147:158481

AB Comps. of reduced isoalpha acids (RIAA), vitamins and minerals are disclosed as well as methods of using the same for the treatment of autoimmune diseases. Addnl. combinations including other compds. are also contemplated. Synergistic properties and methods exploiting such synergy are also disclosed. Thus, pos. effects of a protocol combining an inflammatory-modulating medical food, reduced isoalpha acids, vitamin D3, Zn, Se, and diet were demonstrated on a patient with a history of Crohns' disease and several other symptoms related to immune-inflammatory conditions.

L11 ANSWER 5 OF 13 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2007:641256 CAPLUS

DOCUMENT NUMBER: 147:64520

TITLE: Protein kinase modulation and inflammatory response inhibition by hops and Acacia products

INVENTOR(S): Tripp, Matthew L.; Babish, John G.; Bland, Jeffrey; Hall, Amy Jennae; Konda, Veera; Pacioretty, Linda; Desai, Anu

PATENT ASSIGNEE(S): Metaproteomics, LLC, USA

SOURCE: PCT Int. Appl., 164pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007067812	A2	20070614	WO 2006-US47196	20061211
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			

US 2007154576	A1	20070705	US 2006-636867	20061211
---------------	----	----------	----------------	----------

PRIORITY APPLN. INFO.: US 2005-748931P P 20051209

AB Botanical compds. to modulate kinase activity are disclosed. The compds. and methods disclosed also inhibit expression of COX-2, inhibit synthesis of prostaglandins selectively in target cells, and inhibit inflammatory response selectively. The compns. contain at least one fraction isolated or derived from hops or Acacia.

L11 ANSWER 6 OF 13 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2007:197601 CAPLUS

DOCUMENT NUMBER: 146:266824

TITLE: Protein kinase modulation by hops and Acacia products

INVENTOR(S): Tripp, Matthew L.; Babish, John G.; Bland, Jeff; Hall, Amy Jennae; Konda, Veera; Desai, Anu

PATENT ASSIGNEE(S): Metaproteomics, LLC, USA

SOURCE: PCT Int. Appl., 161pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007021694	A2	20070222	WO 2006-US30920	20060809
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
US 2007042063	A1	20070222	US 2006-501393	20060809
PRIORITY APPLN. INFO.:			US 2005-706984P	P 20050809
			US 2005-748931P	P 20051209
AB Botanical compds. to modulate protein kinase activity are disclosed. The compds. and methods disclosed also inhibit expression of COX-2, inhibit synthesis of prostaglandins selectively in target cells, and inhibit inflammatory response selectively. The compns. contain at least one fraction isolated or derived from hops or Acacia.				

L11 ANSWER 7 OF 13 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2007:90620 CAPLUS
 DOCUMENT NUMBER: 146:177186
 TITLE: Treatment modalities for autoimmune diseases
 INVENTOR(S): Tripp, Matthew; Bland, Jeffrey S.; Lerman, Robert; Hall, Amy; Konda, Veera; Desai, Anu
 PATENT ASSIGNEE(S): USA
 SOURCE: U.S. Pat. Appl. Publ., 23pp., Cont.-in-part of U.S. Ser. No. 866,315, abandoned.
 CODEN: USXXCO
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 11
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2007020352	A1	20070125	US 2006-326874	20060106
US 2003008021	A1	20030109	US 2001-885721	20010620
US 7205151	B2	20070417		
US 2004086580	A1	20040506	US 2003-464410	20030618
US 2004115290	A1	20040617	US 2003-464834	20030618
US 2004151792	A1	20040805	US 2003-689856	20031020
US 7270835	B2	20070918		
US 2007166418	A1	20070719	US 2007-649584	20070104
WO 2007081710	A2	20070719	WO 2007-US82	20070104
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH,				

GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
KG, KZ, MD, RU, TJ, TM
WO 2007081729 A2 20070719 WO 2007-US137 20070104
WO 2007081729 A3 20071108

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN,
KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK,
MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO,
RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT,
TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ,
CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH,
GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA

PRIORITY APPLN. INFO.:

US 2001-885721 A2 20010620
US 2002-420383P P 20021021
US 2003-450237P P 20030225
US 2003-400293 B2 20030326
US 2003-401283 B2 20030326
US 2003-464410 A2 20030618
US 2003-464834 A2 20030618
US 2003-689856 A2 20031020
US 2004-866315 B2 20040610
US 2006-326874 A2 20060106

OTHER SOURCE(S): MARPAT 146:177186

AB Compns. of reduced isoalpha acids, vitamins, and minerals are disclosed as well as methods of using the same for the treatment of autoimmune diseases. Addnl. combinations including other compds. are also contemplated. Synergistic properties and methods exploiting such synergy are also disclosed.

L11 ANSWER 8 OF 13 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2006:579641 CAPLUS

DOCUMENT NUMBER: 145:51071

TITLE: Curcuminoid compositions exhibiting synergistic inhibition of the expression and/or activity of cyclooxygenase-2

INVENTOR(S): Babish, John G.; Howell, Terrance M.; Parcioretty, Linda M.

PATENT ASSIGNEE(S): Metaproteomics, LLC, USA

SOURCE: PCT Int. Appl., 36 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006062681	A1	20060615	WO 2005-US41020	20051114
WO 2006062681	A9	20060803		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			

US 2005129791	A1	20050616	US 2004-988393	20041113
US 7279185	B2	20071009		
AU 2005314515	A1	20060615	AU 2005-314515	20051114
CA 2587523	A1	20060615	CA 2005-2587523	20051114
EP 1816915	A1	20070815	EP 2005-851567	20051114
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR				
US 2007141183	A1	20070621	US 2007-701583	20070202
KR 2007086079	A	20070827	KR 2007-713221	20070612
KR 2007086093	A	20070827	KR 2007-713241	20070612
PRIORITY APPLN. INFO.:				
			US 2004-988393	A 20041113
			US 2001-335062P	P 20011026
			US 2002-282236	A1 20021025
			WO 2005-US41018	W 20051114
			WO 2005-US41020	W 20051114

AB A novel formulation is provided that serves to inhibit the inflammatory response in animals. The formulation comprises, as a first component an effective amount of a curcuminoid species and an effective amount of a second component selected from the group consisting of an alpha-acid species, e.g., humulone, cohumulone, isohumulone, hulupone, etc., or a beta-acid species, such as lupulone, colupulone, adlupulone, etc., or derivs. thereof. The composition provides synergistic anti-inflammatory effects in response to phys. or chemical injury or abnormal immune stimulation due to a biol. agent or unknown etiol. Thus, a lotion containing 0.1% curcuminoids and 0.5% humulone or lupulone was prepared and applied to affected areas of patients who have exhibited acne rosacea or psoriasis.

REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 9 OF 13 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2005:963807 CAPLUS

DOCUMENT NUMBER: 143:253900

TITLE: Synergistic anti-inflammatory compositions comprising an isoalpha acid and a reduced isoalpha acid from hops

INVENTOR(S): Babish, John G.; Tripp, Matthew L.; Bland, Jeffrey S.

PATENT ASSIGNEE(S): USA

SOURCE: U.S. Pat. Appl. Publ., 21 pp.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2005192356	A1	20050901	US 2004-789814	20040227
AU 2005219387	A1	20050915	AU 2005-219387	20050226
CA 2557676	A1	20050915	CA 2005-2557676	20050226
WO 2005084680	A1	20050915	WO 2005-US6216	20050226
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1718313	A1	20061108	EP 2005-723895	20050226
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, IS				
CN 1942192	A	20070404	CN 2005-80011831	20050226
JP 2007525525	T	20070906	JP 2007-501034	20050226

KR 2007024500	A	20070302	KR 2006-720065	20060927
US 2007249728	A1	20071025	US 2007-590301	20070501
PRIORITY APPLN. INFO.:			US 2004-789814	A 20040227
			WO 2005-US6216	W 20050226

OTHER SOURCE(S): MARPAT 143:253900

AB The invention provides a composition comprising a reduced isoalpha acid (RIAA), selected from dihydroisohumulone, dihydroisocohumulone and dihydroadhumulone, and isoalpha acid (IAA), selected from isohumulone, isocohumulone, and isoadhumulone, isolated from hops, wherein the RIAA and IAA are in a ratio of about 3:1 to about 1:10. The invention also provides a method of reducing inflammation by administering a composition comprising a reduced isoalpha acid (RIAA) and isoalpha acid (IAA) isolated from hops, wherein the RIAA and IAA are in a ratio of about 3:1 to about 1:10. For example, synergy of PGE2 inhibition produced by four combinations of RIAA and IAA (3:1, 3:2, 1:1 and 1:10, resp.) was demonstrated in Raw 264.7 cells. Particularly relevant synergy occurred at the 1:1 and 1:10 RIAA/IAA ratios, at RIAA concns. <0.58 µg/mL and RIAA concns. >0.31 µg/mL.

L11 ANSWER 10 OF 13 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2004:936070 CAPLUS

DOCUMENT NUMBER: 141:400871

TITLE: Anti-inflammatory pharmaceutical compositions for reducing inflammation and the treatment or prevention of gastric toxicity

INVENTOR(S): Babish, John G.; Tripp, Matthew L.; Bland, Jeffrey S.; Howell, Terrence; Darland, Gary K.; Lerman, Robert H.; Lukaczer, Daniel O.

PATENT ASSIGNEE(S): USA

SOURCE: U.S. Pat. Appl. Publ., 49 pp., Cont.-in-part of U.S. Ser. No. 689,856.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 11

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2004219240	A1	20041104	US 2004-774048	20040204
US 2003008021	A1	20030109	US 2001-885721	20010620
US 7205151	B2	20070417		
US 2004086580	A1	20040506	US 2003-464410	20030618
US 2004115290	A1	20040617	US 2003-464834	20030618
US 2004151792	A1	20040805	US 2003-689856	20031020
US 7270835	B2	20070918		
AU 2004283065	A1	20050506	AU 2004-283065	20040521
CA 2526804	A1	20050506	CA 2004-2526804	20040521
WO 2005039483	A2	20050506	WO 2004-US16043	20040521
WO 2005039483	A3	20050929		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

EP 1626731	A2	20060222	EP 2004-809400	20040521
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				
JP 2007527407	T	20070927	JP 2006-533298	20040521

MX 2005PA12584	A	20060525	MX 2005-PA12584	20051122
US 2006141081	A1	20060629	US 2006-355145	20060215
US 2006141082	A1	20060629	US 2006-355306	20060215
US 2007202208	A1	20070830	US 2006-557293	20061220
PRIORITY APPLN. INFO.:			US 2001-885721	A2 20010620
			US 2002-420383P	P 20021021
			US 2003-450237P	P 20030225
			US 2003-400293	B2 20030326
			US 2003-401283	B2 20030326
			US 2003-472460P	P 20030522
			US 2003-464410	A2 20030618
			US 2003-464834	A2 20030618
			US 2003-689856	A2 20031020
			US 2004-774048	A 20040204
			WO 2004-US16043	W 20040521

OTHER SOURCE(S): MARPAT 141:400871

AB The invention provides hops (*Humulus lupulus*) exts. or derivs. thereof, such as humulone, cohumulone, adhumulone, isohumulone, etc., for use in treating a patient prophylactically and/or therapeutically for ulcerogenic-type disorders of the stomach and/or intestines. The ulcerogenic disorders can be induced chemical, environmentally, by infection, and/or by stress. The invention also provides a pharmaceutical composition comprising an active amount of hops exts. or derivs. thereof, in combination with an analgesic compound and/or an anti-inflammatory compound. The invention further provides for use of hops exts. or derivs. thereof, significantly reducing and/or therapeutically treating ulcerogenic-type disorders of the stomach and/or intestines. For example, the hop preparation Redihop containing rho-iso- α -acids when combined with NSAIDs (ibuprofen and aspirin) not only attenuated the gastropathy of NSAIDs by decreasing an inhibition of PGE2 synthesis in AGS human gastric mucosal cells, but also increased therapeutic indexes of both ibuprofen and aspirin.

L11 ANSWER 11 OF 13 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2004:633066 CAPLUS

DOCUMENT NUMBER: 141:179610

TITLE: pharmaceutical and nutraceutical compositions containing extracts from hop and rosemary for treatment and prevention of inflammatory-related disorders

INVENTOR(S): Tripp, Matthew L.; Babish, John G.; Bland, Jeffrey S.; Darland, Gary K.; Lerman, Robert; Lukaczer, Daniel O.; Liska, Deann J.; Howell, Terrence

PATENT ASSIGNEE(S): USA

SOURCE: U.S. Pat. Appl. Publ., 66 pp., Cont.-in-part of U.S. Pat. Appl. 2004 86,580.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 11

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----
US 2004151792	A1	20040805	US 2003-689856	20031020
US 7270835	B2	20070918		
US 2003008021	A1	20030109	US 2001-885721	20010620
US 7205151	B2	20070417		
US 2004086580	A1	20040506	US 2003-464410	20030618
US 2004115290	A1	20040617	US 2003-464834	20030618
US 2004219240	A1	20041104	US 2004-774048	20040204
AU 2004283065	A1	20050506	AU 2004-283065	20040521
CA 2526804	A1	20050506	CA 2004-2526804	20040521
WO 2005039483	A2	20050506	WO 2004-US16043	20040521
WO 2005039483	A3	20050929		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,

CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
 GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
 LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,
 NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,
 TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
 RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,
 AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
 EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE,
 SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE,
 SN, TD, TG

EP 1626731 A2 20060222 EP 2004-809400 20040521
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
 IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR
 JP 2007527407 T 20070927 JP 2006-533298 20040521
 MX 2005PA12584 A 20060525 MX 2005-PA12584 20051122
 US 2007020352 A1 20070125 US 2006-326874 20060106
 US 2006141081 A1 20060629 US 2006-355145 20060215
 US 2006141082 A1 20060629 US 2006-355306 20060215
 US 2006177531 A1 20060810 US 2006-403016 20060412
 US 2007281045 A1 20071206 US 2006-635305 20061207
 US 2007202208 A1 20070830 US 2006-557293 20061220
 US 2007166418 A1 20070719 US 2007-649584 20070104
 US 2007184133 A1 20070809 US 2007-729696 20070329

PRIORITY APPLN. INFO.:

US 2001-885721 A2 20010620
 US 2002-420383P P 20021021
 US 2003-450237P P 20030225
 US 2003-400293 B2 20030326
 US 2003-401283 B2 20030326
 US 2003-464410 A2 20030618
 US 2003-464834 A2 20030618
 US 2003-472460P P 20030522
 US 2003-689856 A2 20031020
 US 2004-774048 A 20040204
 WO 2004-US16043 W 20040521
 US 2004-866315 B2 20040610
 US 2005-748907P P 20051209
 US 2006-326874 A2 20060106

OTHER SOURCE(S): MARPAT 141:179610

AB A natural formulation of compds. that would to modulate
 inflammation is disclosed. The formulation would also inhibit
 expression of COX-2, inhibit synthesis of prostaglandins selectively in
 target cells, and inhibit inflammatory response selectively in target
 cells. The compns. containing at least one fraction isolated or derived from
 hops. Other embodiments relate to combinations of components, including
 at least one fraction isolated or derived from hops, tryptanthrin and
 conjugates thereof, rosemary, an extract or compound derived from rosemary, a
 triterpene species, or a diterpene lactone or derivs. or conjugates
 thereof. For example, an oral dietary supplement containing isocohumulone,
 dihydroadhumulone, tetrahydroisocohumulone, hexahydroisohumulone from
 rosemary was found to be able to normalization the joint function after
 two to ten doses.

L11 ANSWER 12 OF 13 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2004:493479 CAPLUS

DOCUMENT NUMBER: 141:33790

TITLE: Modulation of inflammation by hops fractions
 and derivatives

INVENTOR(S): Tripp, Matthew L.; Babish, John G.; Bland, Jeffrey S.;
 Darland, Gary K.; Lerman, Robert; Lukaczer, Daniel O.;
 Liska, DeAnn J.; Howell, Terrence

PATENT ASSIGNEE(S): USA

SOURCE: U.S. Pat. Appl. Publ., 26 pp., Cont.-in-part of US
 Ser. No. 400,293, abandoned.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 11
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2004115290	A1	20040617	US 2003-464834	20030618
US 2003008021	A1	20030109	US 2001-885721	20010620
US 7205151	B2	20070417		
CA 2503196	A1	20040506	CA 2003-2503196	20031020
WO 2004037180	A2	20040506	WO 2003-US33362	20031020
WO 2004037180	A3	20040930		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2003286549	A1	20040513	AU 2003-286549	20031020
US 2004151792	A1	20040805	US 2003-689856	20031020
US 7270835	B2	20070918		
EP 1558271	A2	20050803	EP 2003-777751	20031020
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
JP 2006508182	T	20060309	JP 2005-501640	20031020
NZ 539642	A	20070126	NZ 2003-539642	20031020
US 2004219240	A1	20041104	US 2004-774048	20040204
AU 2004283065	A1	20050506	AU 2004-283065	20040521
CA 2526804	A1	20050506	CA 2004-2526804	20040521
WO 2005039483	A2	20050506	WO 2004-US16043	20040521
WO 2005039483	A3	20050929		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1626731	A2	20060222	EP 2004-809400	20040521
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				
JP 2007527407	T	20070927	JP 2006-533298	20040521
MX 2005PA04288	A	20050802	MX 2005-PA4288	20050421
MX 2005PA12584	A	20060525	MX 2005-PA12584	20051122
US 2007020352	A1	20070125	US 2006-326874	20060106
US 2006127511	A1	20060615	US 2006-344552	20060130
US 2006127512	A1	20060615	US 2006-344554	20060130
US 2006127516	A1	20060615	US 2006-344559	20060130
US 2006141081	A1	20060629	US 2006-355145	20060215
US 2006141082	A1	20060629	US 2006-355306	20060215
US 2006177531	A1	20060810	US 2006-403016	20060412
US 2006193933	A1	20060831	US 2006-403034	20060412
US 2007281045	A1	20071206	US 2006-635305	20061207
US 2007202208	A1	20070830	US 2006-557293	20061220
US 2007166418	A1	20070719	US 2007-649584	20070104
US 2007160692	A1	20070712	US 2007-532388	20070321
PRIORITY APPLN. INFO.:			US 2001-885721	A2 20010620

US 2002-420383P	P	20021021
US 2003-450237P	P	20030225
US 2003-400293	B2	20030326
US 2003-401283	B2	20030326
US 2003-472460P	P	20030522
US 2003-464410	A	20030618
US 2003-464834	A	20030618
US 2003-689856	A2	20031020
WO 2003-US33362	W	20031020
US 2004-774048	A	20040204
WO 2004-US16043	W	20040521
US 2004-866315	B2	20040610
US 2005-748907P	P	20051209
US 2006-326874	A2	20060106

OTHER SOURCE(S): MARPAT 141:33790

AB A natural formulation of compds. for the modulation of inflammation is disclosed. The formulation would also inhibit expression of COX-2, inhibit synthesis of prostaglandins selectively in target cells, and inhibit inflammatory response selectively in target cells. The compns. contain at least one fraction isolated or derived from hops.

L11 ANSWER 13 OF 13 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2004:372602 CAPLUS

DOCUMENT NUMBER: 140:368679

TITLE: Synergistic compositions that treat or inhibit pathological conditions associated with inflammatory response

INVENTOR(S): Tripp, Matthew L.; Babish, John G.; Bland, Jeffrey S.; Darland, Gary K.; Lerman, Robert; Lukaczer, Daniel O.; Liska, Deann J.; Howell, Terrence

PATENT ASSIGNEE(S): USA

SOURCE: U.S. Pat. Appl. Publ., 41 pp., Cont.-in-part of U.S. Ser. No. 400,293, abandoned.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 11

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2004086580	A1	20040506	US 2003-464410	20030618
CA 2503196	A1	20040506	CA 2003-2503196	20031020
WO 2004037180	A2	20040506	WO 2003-US33362	20031020
WO 2004037180	A3	20040930		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2003286549	A1	20040513	AU 2003-286549	20031020
US 2004151792	A1	20040805	US 2003-689856	20031020
US 7270835	B2	20070918		
EP 1558271	A2	20050803	EP 2003-777751	20031020
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
JP 2006508182	T	20060309	JP 2005-501640	20031020
NZ 539642	A	20070126	NZ 2003-539642	20031020
US 2004219240	A1	20041104	US 2004-774048	20040204

AU 2004283065	A1	20050506	AU 2004-283065	20040521
CA 2526804	A1	20050506	CA 2004-2526804	20040521
WO 2005039483	A2	20050506	WO 2004-US16043	20040521
WO 2005039483	A3	20050929		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

EP 1626731	A2	20060222	EP 2004-809400	20040521
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				
JP 2007527407	T	20070927	JP 2006-533298	20040521
MX 2005PA04288	A	20050802	MX 2005-PA4288	20050421
MX 2005PA12584	A	20060525	MX 2005-PA12584	20051122
US 2007020352	A1	20070125	US 2006-326874	20060106
US 2006127513	A1	20060615	US 2006-344555	20060130
US 2006127514	A1	20060615	US 2006-344556	20060130
US 2006127515	A1	20060615	US 2006-344557	20060130
US 2006127517	A1	20060615	US 2006-344561	20060130
US 2006141081	A1	20060629	US 2006-355145	20060215
US 2006141082	A1	20060629	US 2006-355306	20060215
US 2006177531	A1	20060810	US 2006-403016	20060412
US 2007281045	A1	20071206	US 2006-635305	20061207
US 2007202208	A1	20070830	US 2006-557293	20061220
US 2007166418	A1	20070719	US 2007-649584	20070104
US 2007160692	A1	20070712	US 2007-532388	20070321
US 2007184133	A1	20070809	US 2007-729696	20070329

PRIORITY APPLN. INFO.:

US 2002-420383P	P	20021021
US 2003-450237P	P	20030225
US 2003-400293	B2	20030326
US 2003-401283	B2	20030326
US 2001-885721	A2	20010620
US 2003-472460P	P	20030522
US 2003-464410	A	20030618
US 2003-464834	A	20030618
US 2003-689856	A2	20031020
WO 2003-US33362	W	20031020
US 2004-774048	A	20040204
WO 2004-US16043	W	20040521
US 2004-866315	B2	20040610
US 2005-748907P	P	20051209
US 2006-326874	A2	20060106

OTHER SOURCE(S): MARPAT 140:368679

AB A natural formulation of compds. that would modulate inflammation is disclosed. The formulation would also inhibit expression of COX-2, inhibit synthesis of prostaglandins selectively in target cells, and inhibit inflammatory response selectively in target cells. The compns. contains at least one fraction isolated or derived from hops. Other embodiments relate to combinations of components, including at least one fraction isolated or derived from hops, tryptanthrin and conjugates thereof, rosemary, an extract or compound derived from rosemary, a triterpene species, or a diterpene lactone or derivs. or conjugates thereof. For example, a synergistic inhibition of PGE2 synthesis in target cells by hop CO2 extract containing 30 to 60% alpha-acids and 15 to 45% beta-acids in combination with triterpenoids oleanolic acid and ursolic acid was exhibited.

=> file reg		
COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	53.67	54.36
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
	ENTRY	SESSION
CA SUBSCRIBER PRICE	-10.40	-10.40

FILE 'REGISTRY' ENTERED AT 10:49:49 ON 03 FEB 2008
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
 COPYRIGHT (C) 2008 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
 provided by InfoChem.

STRUCTURE FILE UPDATES: 1 FEB 2008 HIGHEST RN 1001383-72-7
 DICTIONARY FILE UPDATES: 1 FEB 2008 HIGHEST RN 1001383-72-7

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 29, 2007

Please note that search-term pricing does apply when
 conducting SmartSELECT searches.


REGISTRY includes numerically searchable data for experimental and
 predicted properties as well as tags indicating availability of
 experimental property data in the original document. For information
 on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=> s DIHYDROISOHUMULONE
 L12 1 DIHYDROISOHUMULONE

=> d str cn rn

L12 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2008 ACS on STN



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

CN 1-Butanone, 3-methyl-1-[2,3,5-trihydroxy-3-(1-hydroxy-4-methyl-3-penten-1-yl)-4-(3-methyl-2-buten-1-yl)-1-cyclopenten-1-yl]- (CA INDEX NAME)

OTHER CA INDEX NAMES:

CN 1-Butanone, 3-methyl-1-[2,3,5-trihydroxy-3-(1-hydroxy-4-methyl-3-pentenyl)-4-(3-methyl-2-butenyl)-1-cyclopenten-1-yl]- (9CI)

OTHER NAMES:

CN Dihydroisohumulone

RN 685110-35-4 REGISTRY

=> s dihydroisocohumulone

L13 1 DIHYDROISOCOHUMULONE

=> d str cn rn L13

L13 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2008 ACS on STN

CN 2-Cyclopenten-1-one, 3,4-dihydroxy-5-(3-methyl-2-buten-1-yl)-4-(4-methyl-1-oxo-3-penten-1-yl)-2-(2-methyl-1-oxopropyl)-, dihydro deriv. (CA INDEX NAME)

OTHER CA INDEX NAMES:


CN 2-Cyclopenten-1-one, 3,4-dihydroxy-5-(3-methyl-2-butenyl)-4-(4-methyl-1-oxo-3-pentenyl)-2-(2-methyl-1-oxopropyl)-, dihydro deriv. (9CI)

OTHER NAMES:

CN Dihydroisocohumulone

RN 790664-64-1 REGISTRY

CM 1



=> s dihydroisoadhumulone

L14 1 DIHYDROISOADHUMULONE

=> d str cn rn L14

L14 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2008 ACS on STN


CN 2-Cyclopenten-1-one, 3,4-dihydroxy-5-(3-methyl-2-butenyl)-2-(2-methyl-1-oxobutyl)-4-(4-methyl-1-oxo-3-pentenyl)-, dihydro deriv. (9CI) (CA INDEX NAME)

OTHER NAMES:

CN Dihydroisoadhumulone

RN 790664-65-2 REGISTRY

CM 1



=> file caplus

COST IN U.S. DOLLARS

FULL ESTIMATED COST

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE	TOTAL
ENTRY	SESSION
24.67	79.03

SINCE FILE	TOTAL
ENTRY	SESSION

CA SUBSCRIBER PRICE

0.00

-10.40

FILE 'CAPLUS' ENTERED AT 10:53:46 ON 03 FEB 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 3 Feb 2008 VOL 148 ISS 6
FILE LAST UPDATED: 1 Feb 2008 (20080201/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>

```
=> s l12 or L13 or L14
      20 L12
      11 L13
      2 L14
L15      20 L12 OR L13 OR L14

=> dup rem L15
PROCESSING COMPLETED FOR L15
L16      20 DUP REM L15 (0 DUPLICATES REMOVED)
```

```
=> s inflammation
      188875 INFLAMMATION
      2184 INFLAMMATIONS
L17      189766 INFLAMMATION
      (INFLAMMATION OR INFLAMMATIONS)
```

```
=> s L16 and L17
L18      20 S L16
L19      15 L18 AND L17
```

```
=> s L19 NOT L11
L20      2 L19 NOT L11
```

```
=> d 1-2 L20 ibib abs
```

L20 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2008 ACS.on STN

ACCESSION NUMBER: 2007:758686 CAPLUS

DOCUMENT NUMBER: 147:150811

TITLE: Pharmaceutical compositions containing Hops and rosemary extracts and terpenes for regulating inflammatory response

INVENTOR(S): Tripp, Matthew L.; Babish, John G.; Bland, Jeffrey S.; Darland, Gary; Lerman, Robert; Lukaczer, Daniel O.; Liska, Deann J.; Howell, Terrence

PATENT ASSIGNEE(S): USA

SOURCE: U.S. Pat. Appl. Publ., 63pp., Cont.-in-part of U.S. Ser. No. 464,834.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English
FAMILY ACC. NUM. COUNT: 11
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2007160692	A1	20070712	US 2007-532388	20070321
US 2004086580	A1	20040506	US 2003-464410	20030618
US 2004115290	A1	20040617	US 2003-464834	20030618
WO 2004037180	A2	20040506	WO 2003-US33362	20031020
WO 2004037180	A3	20040930		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE,
GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK,
LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ,
OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM,
TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,
FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR,
BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.:
US 2002-420383P P 20021021
US 2003-450237P P 20030225
US 2003-400293 B2 20030326
US 2003-401283 B2 20030326
US 2003-464410 A2 20030618
US 2003-464834 A2 20030618
WO 2003-US33362 W 20031020
US 2001-885721 A2 20010620

AB A natural formulation of compds. that would to modulate inflammation is disclosed. The formulation would also inhibit expression of COX-2, inhibit synthesis of prostaglandins selectively in target cells, and inhibit inflammatory response selectively in target cells. The compns. containing at least one fraction isolated or derived from hops. Other embodiments relate to combinations of components, including at least one fraction isolated or derived from hops, tryptanthrin and conjugates thereof, rosemary, an extract or compound derived from rosemary, a triterpene species, or a diterpene lactone or derivs. or conjugates thereof.

L20 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2005:961505 CAPLUS

DOCUMENT NUMBER: 143:241995

TITLE: Synergistic antiinflammatory pharmaceutical compositions and related methods using a hops-derived fraction and curcuminoids or methylxanthines

INVENTOR(S): Babish, John G.; Tripp, Matthew L.; Bland, Jeffrey S.

PATENT ASSIGNEE(S): USA

SOURCE: U.S. Pat. Appl. Publ., 37 pp.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2005191375	A1	20050901	US 2004-789817	20040227
AU 2005218319	A1	20050915	AU 2005-218319	20050226
CA 2557643	A1	20050915	CA 2005-2557643	20050226
WO 2005084230	A2	20050915	WO 2005-US6147	20050226
WO 2005084230	A3	20051215		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,

LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,
 NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM,
 SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
 RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,
 AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
 EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT,
 RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML,
 MR, NE, SN, TD, TG

EP 1718312 A2 20061108 EP 2005-723839 20050226
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
 IE, SI, LT, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, IS
 CN 1946409 A 20070411 CN 2005-80011830 20050226
 JP 2007525523 T 20070906 JP 2007-501015 20050226
 KR 2007018046 A 20070213 KR 2006-720068 20060927
 US 2007185213 A1 20070809 US 2007-590424 20070402
 PRIORITY APPLN. INFO.: US 2004-789817 A 20040227
 WO 2005-US6147 W 20050226

OTHER SOURCE(S): MARPAT 143:241995

AB The invention provides compns. containing a fraction isolated or derived from
 hops and a methylxanthine. The invention addnl. provides compns. containing a
 fraction derived from hops and a curcuminoid. The invention also provides
 methods of using such compns. to reduce inflammation.

=> s L15 NOT L11
 L21 7 L15 NOT L11

=> dup rem L21
 PROCESSING COMPLETED FOR L21
 L22 7 DUP REM L21 (0 DUPLICATES REMOVED)

=> s L21 NOT L20
 L23 5 L21 NOT L20

=> d 1-5 L23 ibib abs

L23 ANSWER 1 OF 5 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2007:1377440 CAPLUS

DOCUMENT NUMBER: 148:49085

TITLE: Device and method for separating humulone and mixture
 of lupulone and hop essential oil from hop or hop
 extract

INVENTOR(S): Zhu, Lixin; Ke, Jie

PATENT ASSIGNEE(S): Beijing Leebo Megahops Co., Ltd., Peop. Rep. China

SOURCE: Faming Zhuanli Shenqing Gongkai Shuomingshu, 13pp.
 CODEN: CNXXEV

DOCUMENT TYPE: Patent

LANGUAGE: Chinese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----
CN 101078000	A	20071128	CN 2006-10080630	20060523
PRIORITY APPLN. INFO.:			CN 2006-10080630	20060523

AB The title method comprises (1) mixing hop/hop extract with liquid carbon
 dioxide to dissolve humulone and mixture of lupulone and hop essential oil
 contained in the hop/hop extract, (2) adsorbing humulone with adsorbent, (3)
 eluting the adsorbed humulone, evaporating, and acidifying to obtain humulone,
 and (4) allowing the mixture of lupulone and hop essential oil to flow out
 with liquid carbon dioxide, and gasifying to obtain mixture of lupulone and
 hop essential oil. The adsorbent is calcium silicate, magnesium silicate,
 zinc silicate, or combination thereof. The title device comprises a liquid
 carbon dioxide tank, a high pressure pipe column, an adsorbent pipe
 column, a humulone collecting tank, a separating tank, and a receiving tank.

The method has the advantages of high separation efficiency and no pollution.

L23 ANSWER 2 OF 5 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2006:165354 CAPLUS

DOCUMENT NUMBER: 144:329974

TITLE: A rapid and low-cost method for quantification of reduced iso- α -acids in brewing

AUTHOR(S): Bolivar, Alexis; Gasparri, Monica; Zufall, Carsten

CORPORATE SOURCE: Corporative Quality, Innovation and Development

Department, Cerveceria Polar C. A., Caracas, Venez.

SOURCE: Journal of the American Society of Brewing Chemists (2006), 64(1), 39-46

CODEN: JSBCD3; ISSN: 0361-0470

PUBLISHER: American Society of Brewing Chemists, Inc.

DOCUMENT TYPE: Journal

LANGUAGE: English

AB A rapid HPLC method for routine wort and beer anal. during production has been developed. The method is based on the separation of the reduced iso- α -acids such as dihydro-, tetrahydro-, and hexahydro-iso- α -acids. This is done by means of a new column technol. and direct injection of the sample. The new method is significantly faster and more economical than are the existing methods, obtaining 86% savings in time and 60% savings in cost. The method has been validated and implemented in our five labs. with excellent results in repeatability and reproducibility.

REFERENCE COUNT: 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L23 ANSWER 3 OF 5 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2005:78545 CAPLUS

DOCUMENT NUMBER: 142:315625

TITLE: Photooxidative degradation of beer bittering principles: A key step on the route to lightstruck flavor formation in beer

AUTHOR(S): Huvaere, Kevin; Andersen, Mogens L.; Skibsted, Leif

H.; Heyerick, Arne; De Keukeleire, Denis

CORPORATE SOURCE: Faculty of Pharmaceutical Sciences, Laboratory of

Pharmacognosy and Phytochemistry, Ghent University,

Ghent, B-9000, Belg.

SOURCE: Journal of Agricultural and Food Chemistry (2005), 53(5), 1489-1494

CODEN: JAFCAU; ISSN: 0021-8561

PUBLISHER: American Chemical Society

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Isohumulones, dihydroisohumulones, tetrahydroisohumulones, and humulinones, important hop-derived bittering compds. in beer, were shown to give rise to reactive triacylmethyl radicals on interaction with triplet-excited riboflavin after spin trapping by 5,5-dimethyl-1-pyrroline N-oxide or 2-methyl-2-nitrosopropane, followed by ESR spectroscopy combined with spectral simulation. Electron abstraction from the ionized β -tricarboxyl chromophore, which is common to all five-membered ring hop derivs., is the initial event on photoinduced degradation. Radicaloid decomposition of isohumulones leads to precursors for 3-methylbut-2-ene-1-thiol, the lightstruck constituent in beer. Interaction of reduced derivs. of isohumulones with triplet-excited riboflavin furnished radical precursors of volatile aldehydes, which may lead to the development of unpleasant stale or cardboard flavors.

REFERENCE COUNT: 26 THERE ARE 26 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L23 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2004:722575 CAPLUS

DOCUMENT NUMBER: 142:5781

TITLE: Photooxidative degradation of beer bittering

principles: product analysis with respect to
lightstruck flavor formation

AUTHOR(S): Huvaere, Kevin; Sinnaeve, Bart; Van Bocxlaer, Jan; De
Keukeleire, Denis

CORPORATE SOURCE: Faculty of Pharmaceutical Sciences, Laboratory of
Pharmacognosy and Phytochemistry, Ghent University,
Ghent, B-9000, Belg.

SOURCE: Photochemical & Photobiological Sciences (2004), 3(9),
854-858
CODEN: PPSHCB; ISSN: 1474-905X

PUBLISHER: Royal Society of Chemistry

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Isohumulones, the main bittering agents in beer, are decomposed by
light-induced reactions, thereby leading to radical precursors on the
pathway to lightstruck flavor formation. Excited flavins, formed on
visible-light irradiation, readily interact with isohumulones, as well as with
reduced and oxidized derivs. thereof. From identification of both
volatile and non-volatile reaction products thus formed, feasible degradation
mechanisms are proposed.

REFERENCE COUNT: 22 THERE ARE 22 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L23 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2004:569687 CAPLUS

DOCUMENT NUMBER: 141:111612

TITLE: Hop extracts as anti-inflammatory cyclooxygenase-2-
selective inhibitors

INVENTOR(S): Kuhrts, Eric H.

PATENT ASSIGNEE(S): USA

SOURCE: U.S. Pat. Appl. Publ., 8 pp.
CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2004137096	A1	20040715	US 2003-340183	20030109
US 7144590	B2	20061205		
WO 2004062611	A2	20040729	WO 2004-US613	20040109
WO 2004062611	A3	20050407		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ				
BR 2004006715	A	20051220	BR 2004-6715	20040109
JP 2006515621	T	20060601	JP 2006-500893	20040109
MX 2005PA07433	A	20060407	MX 2005-PA7433	20050708
US 2007003646	A1	20070104	US 2006-452095	20060612
US 7279186	B2	20071009		
US 2007254962	A1	20071101	US 2007-736551	20070417
PRIORITY APPLN. INFO.:			US 2003-340183	A 20030109
			WO 2004-US613	W 20040109
			US 2006-452095	A1 20060612

AB Disclosed is a novel anti-inflammatory pharmaceutical composition that exhibits
potent and selective inhibition of the cyclooxygenase-2 (COX-2) enzyme.
The formulation consists of a hops extract that exhibits COX-2 selectivity as
defined by dividing the IC50 COX-2/IC50COX-1 concns. that are determined by
testing with the William Harvey Whole Blood Assay (WHMA), and fall in the
range 0.011-0.2. Such compns. may also optionally contain high levels of
 α -acids and low levels of β -acids, some flavonoid compds., and
virtually no essential oils. Such compns. are useful for treating
conditions that manifest as inflammatory pain, or are impacted by the

COX-2 enzyme. The compns. are particularly beneficial for treating osteoarthritis and rheumatoid arthritis, and can be used for chronic pain with reduced gastric side-effects. A hops extract contained α -acids 88, β -acids 3.2, and iso- α acids 3%. The hops extract was more potent and selective than ibuprofen for inhibition of COX-2.

REFERENCE COUNT: 12 THERE ARE 12 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=>
=>

EAST Search History

Ref #	Hits	Search Query	DBs	Default Operator	Plurals	Time Stamp
S69	1	"6583322"	USPAT	OR	ON	2008/01/21 15:31
S70	105	isohumulone or isocohumulone or isoadhumulone	USPAT	OR	ON	2008/01/20 21:48
S71	41117	inflammation	USPAT	OR	ON	2008/01/20 21:49
S72	4	S70 and S71	USPAT	OR	ON	2008/01/20 21:48
S73	278	isohumulone or isocohumulone or isoadhumulone	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2008/01/20 21:49
S74	138011	inflammation	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2008/01/20 21:49
S75	46	S73 and S74	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2008/01/20 21:49
S76	0	"2003000185"	USPAT	OR	ON	2008/01/21 15:31
S77	5	"2003000185"	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2008/01/21 16:43
S78	18	"5073396"	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2008/01/21 16:46

EAST Search History

S79	0	rhohumulone	US-PGPUB; USPAT; USOCR; FPRS; EPO; JPO; DERWENT; IBM_TDB	OR	ON	2008/01/21 16:46
S80	14626	hops	USPAT	OR	ON	2008/01/21 16:47
S81	30	"isoalpha acid"	USPAT	OR	ON	2008/01/21 16:47
S82	1	"20020086062"	US-PGPUB; USPAT	OR	ON	2008/01/21 16:54